Published evidence of delays in treatment for pediatric rSE was not associated with improvement in time to treatment but with an increase in those who received BZD.
The FDA has approved Fintepla® (fenfluramine; Zogenix) oral solution for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.
Hallucinatory experiences are also strong risk markers for suicidal behavior in those with seizures.
Consensus recommendations are provided to optimize the care of people with epilepsy.
Naoto Kuroda, MD, of Wayne State University, in Detroit, Michigan, provided a checklist for clinicians about what they should ask and look out for in a telemedicine session with patients with epilepsy.
Dissociative seizures are paroxysmal episodes distinctive from epileptic seizures or syncope, and patients with dissociative seizures often have comorbid psychiatric difficulties.
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
During COVID-19, clinicians will be challenged by a lack of ICU resources and ventilators to manage patients with status epilepticus.
A brief communication provides information about the associations between, and the considerations for, COVID-19 and epilepsy.
The STOPBAG2 scoring instrument, which incorporates sleep-related symptoms and continuous variables for age and BMI, offers greater discriminatory power for predicting all levels of OSA severity in adults with epilepsy.